Management of HCV-HIV patients;Prise en charge des patients co-infectés VIH-VHC

Gastroenterologie Clinique et Biologique

Volumn 31, Issue 8-9 C3, 2007, Pages

  Pol, Stanislas ^a   Cacoub, Patrice ^b   Pialoux, Gilles ^c   Benhamou, Yves ^b   Halfon, Philippe ^d   Rosenthal, Eric ^e   Perronne, Christian ^f  

^a Institut Cochin   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HÔPITAL TENON   (France)

^d Laboratoire de virologie Alphabio   (France)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^f RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINTERFERON; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; ZIDOVUDINE;

ARTICLE; DISEASE SEVERITY; DRUG ABUSE; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; LIVER TOXICITY; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; STEATOSIS; VIRUS LOAD;

EID: 35948962818     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0399-8320(07)92557-9     Document Type: Article

References (30)

1. Pol S, Lebray P, Vallet-Pichard A. HIV infection and hepatic enzyme abnormalities:intricacies of the pathogenic mechanisms. Clin Infect Dis. 2004;38:S65-72.
2. Soriano V, Rodriguez-Rosado R, Garcia-Samaniego J. Management of chronic hepatitis C in HIV-infected patients. AIDS 1999;13:539-46.
3. Rosenthal E, Pialoux G, Bernard N, Pradier C, Rey D, Bentata M, et al. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study)*. J Viral Hepat 2007;14:183-8.
4. Salmon-Ceron D, Lewden C, Morlat P, Bevilacqua S, Jougla E, Bonnet F, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005;42:799-805.
5. Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Charlotte F, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS 2003;17:721-5.
6. Sterling R, Lissen E, Clumeck N, Sola R, Correa M, Montaner J, et al. Development of non-invasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317-25.
7. de Ledinghen V, Douvin C, Kettaneh A, Ziol M, Roulot D, Marcellin P, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr. 2006;41:175-9.
8. Cacoub P, Carrat F, Bedossa P, Lambert J, Pénaranda G, Perronne C, et al. Independent assessment of non invasive liver fibrosis biomarkers in HIV-HCV co-infected patients:the Fibrovic study. Hepatology 2006;44:270A (Abstract 215).
9. Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palù G, et al. Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005;42:615-24.
10. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-9.
11. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-50.
12. Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, Sanchez-Tapias JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004;18:27-36.
13. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel F, Morand P, et al. A randomized controlled trial of pegylated interferon alfa-2b plus ribavirin versus standard interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C in HIV co-infected patients (RIBAVIC-ANRS HC02). JAMA 2004;292:2839-48.
14. Cacoub P, Rosenthal E, Halfon P, Sene D, Perronne C, Pol S. Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life. J Viral Hepatitis 2006;13:678-82.
15. Fontaine H, Chaix M-L, Lagneau J-L, Bréchot C, Pol S. Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa. Lancet 2000;356:41.
16. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9.
17. Reddy KR, Hadziyannis SJ, Diago M, Marcellin P, Lopez-Talavera JC, Wright TL. The influence of cumulative peginterferon alfa 2a and ribavirin exposure on sustained virological response rates in patients with genotype 1 chronic hepatitis C [abstract]. J Hepatol 2005;42:217.
18. Serpaggi J, Chaix M-L, Batisse D, Dupont C, Vallet-Pichard A, Fontaine H et al. Sexually transmitted acute infection with clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS 2006;20:233-40.
19. Dominguez S, Ghosn J, Valantin MA, Schraniger A, Simon A, Bonnard P, et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS 2006;20:1157-61.
20. Nunez M, Garcia-Samaniego J, Romero M, Portu J, Barreiro P, Bonet L, et al. The Presco trial: impact of higher ribavirin doses and longer duration of therapy with peginterferon alfa-2A plus ribavirin in HIV-infected patients with chronic hepatitis C. Hepatology 2006;44:326A (Abstract 363).
21. Crespo M, Sauleda S, Esteban JI, Juarez A, Ribera E, Andreu AL, et al. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J Viral Hepatitis 2006;10:1365-2893.
22. Lee SS, Heathcote EJ, Reddy KR, Zeuzem S, Fried MW, Wright TL, et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol 2002;37:500-6.
23. De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000;31:997-1004.
24. Afdhal NH. Role of epoetin alfa in maintaining ribavirin dose. Gastroenterol Clin North Am 2004;33:S25-35.
25. Collantes RS, Younossi ZM. The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. J Clin Gastroenterol 2005;39:S9-13.
26. Pardo M, Castillo I, Navas S, Carreno V. Treatment of chronic hepatitis C with cirrhosis with recombinant human granulocyte colony-stimulating factor plus recombinant interferon-alpha. J Med Virol 1995;45:439-44.
27. Dieterich DT, Wasserman R, Brau N, Hassanein TI, Bini EJ, Bowers PJ, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003;98:2491-9.
28. Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004;40:1450-8.
29. Lebray P, Nalpas B, Vallet-Pichard A, Broissand C, Sobesky R, Serpaggy J, et al. Haematopoietic growth factors in patients with haematotoxicity during chronic hepatitis C treatment: a clinical descriptive analysis. Antiviral Ther 2005; 10:769-76.
30. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, et al. Insulin resistance impairs sustained